ALLSCHWIL, Switzerland, Dec. 17, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that preliminary efficacy data generated in the proof-of-concept study evaluating bosentan (500mg bid) in the indication metastatic melanoma (stage 4) do not support the initiation of a full clinical development program in this indication. The observed safety profile was consistent with earlier findings in clinical studies that led to the approval of bosentan (Tracleer(r) 125mg bid) in pulmonary arterial hypertension (PAH).
